Second/third-line nivolumab vs nivo plus ipilimumab in malignant pleural mesothelioma: Long-term results of IFCT-1501 MAPS2 phase IIR trial with a focus on hyperprogression (HPD)
Journal article published in 2019 by
G. Zalcman 
,
J. Mazieres,
L. Greillier,
S. Brosseau,
S. Lantuejoul,
P. Do,
O. Bylicki,
I. Monnet,
R. Corre,
C. Audigier-Valette,
M. Locatelli-Sanchez,
O. Molinier,
F. Guisier,
T. Urban,
D. Planchard
and other authors.
,
J. Mazieres,
L. Greillier,
S. Brosseau,
S. Lantuejoul,
P. Do,
O. Bylicki,
I. Monnet,
R. Corre,
C. Audigier-Valette,
M. Locatelli-Sanchez,
O. Molinier,
F. Guisier,
T. Urban,
D. Planchard
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 